Guardant Health Introduces Shield™ Test for Colorectal Cancer Screening in Abu Dhabi

Revolutionizing Colorectal Cancer Screening in Abu Dhabi with Guardant Health's Shield™ Test

Guardant Health, Inc. has forged a strategic partnership with the Abu Dhabi Public Health Center (ADPHC) to introduce a groundbreaking non-invasive blood-based colorectal cancer screening program utilizing its innovative Shield™ test. This initiative, facilitated through Hikma Pharmaceuticals PLC and integrated into the M42 healthcare system, targets the alarming late-stage diagnosis rates of colorectal cancer in Abu Dhabi, where it stands as the third most prevalent cancer. Currently, 63% of colorectal cancer cases in the region are diagnosed at advanced stages, underlining the urgent need for improved screening methods. The Shield test will become part of ADPHC's IFHAS comprehensive health screening program, making it accessible at key healthcare facilities across Abu Dhabi, Al Ain, and the Al Dhafra region.

The collaboration aims to enhance participation in colorectal cancer screening and ultimately improve early detection rates. Given the cultural and logistical barriers that often hinder residents from adhering to screening protocols, the program focuses on creating a more inviting and community-oriented screening experience. AmirAli Talasaz, co-CEO of Guardant Health, underscores the lifesaving potential of early detection, stating that it can significantly improve survival rates. This initiative is designed not only to promote health awareness but also to foster a supportive environment for those seeking screening, thus addressing the low adherence rates currently seen in the region.

In its first year, the program is projected to screen around 10,000 individuals, marking a significant step toward combating colorectal cancer in Abu Dhabi. Guardant Health, founded in 2012, has consistently emphasized its commitment to advancing cancer care through innovative blood and tissue tests, coupled with real-world data and AI analytics. This initiative aligns with the company's broader mission to improve patient outcomes across the oncology spectrum, from early detection to treatment decisions for advanced cancer cases. As Guardant Health rolls out this program, it aims to not only transform the landscape of colorectal cancer screening in the UAE but also set a precedent for future public health initiatives focused on precision oncology.

In related news, Guardant Health plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025. The company will host a conference call at 1:30 PM Pacific Time to discuss the results, which will be accessible through the company's website. This event reflects Guardant Health's ongoing commitment to transparency and engagement with stakeholders as it navigates its growth in the precision oncology sector.